Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIBISCUS: Intravenous Interferon Beta-1a vs Dexamethasone in COVID-19
NCT04860518Phase 2Terminated
- Sponsor
- Faron Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interferon beta-1a in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Faron Pharmaceuticals. Primary endpoint: Clinical Status at Day 14 as Measured by WHO 9-point Ordinal Scale. Started Aug 2021; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04860518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860518.